ALL patients, aged between 16 and 40 years, were reported istical package (Berkeley, CA, USA). Kaplan-Meier curves Keywords: bone marrow transplantation; leukemia; graft-versuswere calculated using the product limit method. 4 Comparihost disease; total body irradiation sons of survival probabilities were performed using the logrank test (Mantel-Cox). Curves in the figures were stopped when fewer than three patients remained at risk. Patient-, Introduction disease-, and treatment-related variables were compared between the two age cohorts using the 2 statistical method Because of the association between age and treatment-related for categorical variables. Variables differing significantly toxicities, many centers have restricted allogeneic bone mar-(P Ͻ 0.05) or recognized as potential prognostic factors were row transplantation (BMT) to young patients, usually below included as covariates in a multivariate analysis comparing 40 years of age. In view of the recent improvements in supportpatients at different ages. The Cox proportional hazard ive care and increased experience, some teams propose the regression model 5 was used for the multivariate analysis to same therapeutic approach to older patients, to benefit from the compare the risk of relapse, TRM, LFS, and survival between decreased risk of relapse after BMT. The upper age limit of allothe two cohorts. Multivariate analyses were performed separgeneic BMT as well as for the autologous setting 1-3 is advancately for both the AML and ALL patients. ing. In order to evaluate the feasibility of BMT in patients over 40 years, the results in patients reported to the Acute Leukemia Registry from 1986 to 1992, were analyzed.
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Results
Pretransplant parameters are summarized in Tables 1 and 2  Patients and methods  and pretransplant regimens in Tables 3 and 4 . Pre-and peritransplant characteristics of the two popuPatients lations showed similar distributions for gender ratio, donorrecipient gender matching, FAB classification, and pretransData from 151 patients with AML, 41 with ALL allografted in plant regimen. The populations differed for the interval first remission for de novo leukemias and aged over 40 years, between diagnosis and BMT in the two AML groups, as well were reported to the EBMT registry between January 1986 and as GVHD prophylaxis for AML and ALL. Figures 1 and 2 illusDecember 1992. The closing data for this analysis was the 31 trate the probability of relapse of the two groups in each type December 1993. During the same period, 652 AML and 467 of leukemia, with 19 ± 4% vs 30 ± 3% (P = 0.12) at 5 years for AML (older vs younger) and 38 ± 11% vs 29 ± 3% (P = 0.32) at 4 years for ALL patients. The probability of transplant-related mortality (TRM), was significantly higher for the older group and 4). The causes of non-relapse mortality in AML patients available in the AML group to perform a pair-matched analysis. Three parameters were selected for matching, the conwere mainly due to interstitial pneumonitis (12/51), GVHD (9/51), infectious complications (14/51), and in ALL patients, ditioning regimen, the GVHD prophylaxis and the interval from diagnosis to BMT, greater or shorter than 156 days. The to interstitial pneumonitis (2/13), infections (8/13) and GVHD (2/13). When analyzing AML by age with three subgroups, 302 younger patients were compared to the 151 older AML patients showing a probability of LFS of 48 ± 4% vs 53 ± 3% below 40 years, between 40 and 44 and over 45 years, the difference in terms of TRM was only found for patients over (P = 0.30), of relapse incidence of 19 ± 4% vs 34 ± 3% (P = 0.33), of TRM of 41 ± 5% vs 31 ± 3% (P = 0.053), and sur-45 years of age. Finally, the probability of survival of older and younger patients (Figures 5 and 6 ) was 50 ± 5% vs 55 ± 3% at vival of 50 ± 3% vs 57 ± 3% (P = 0.14) for both the older and younger cohorts respectively. 5 years for AML (P = 0.13), 36 ± 11% vs 54 ± 4% at 4 years for ALL (P = 0.03). Six covariates were selected to perform a multivariate analysis, age, gender, gender matching, pre-transplant regimen, acute GVHD prophylaxis and interval from Discussion diagnosis to BMT. These are shown in Tables 5 and 6 , respectively for AML and ALL. The only favorable factor influencing Allogeneic BMT has become a therapy of choice for patients with acute leukemia. However, until recently, use of this survival in AML was GVHD prevention utilizing the combination of CsA and methotrexate. Finally, enough patients were approach has been limited to younger patients due to the fear Table 6 Multivariate analysis allogeneic BMT for ALL in CR1 Table 3 Allografts for ALL patients: pretransplant regimens and GVHD prevention
Relative risk P value ALL CR1
16-40 years у40 years P value of an increased risk of mortality due to age. Results in the literature support the concept that older patients may also benefit from high-dose therapy followed by allogeneic or autologous stem-cell transplantation especially due to the availability of recent improvements in supportive care. 1, 3 In Figure 3 Transplant-related mortality in AML CR1.
the IBMTR study, 1 a total of 2180 recipients of HLA-identical 45-to 49-year-old cohort a higher risk of interstitial pneumonia. In this study, we have restricted the analysis to AML and ALL in first remission showing a statistical difference in TRM for AML patients in first remission aged over 45. A similar trend was found in ALL over 40 years of age, which could be due to the small group of allografted older patients; however, it can be assumed that more ALL older patients were Ph1+, but no firm conclusion can be drawn from the registry. These data must be interpreted with caution, confirmed in prospective trials comparing, in patients aged 46-60, allogeneic BMT with intensification of chemotherapy and autologous stem-cell transplantation as is the case for current trials with younger patients. This needs to be carried out to avoid or limit selection biases, such as those which may result from patients who did not reach or refused a transplant. This study
Figure 4
Transplant-related mortality in ALL CR1.
nonetheless indicates that, with current patient care, age should not be an absolute barrier. Cytogenetic data were not available in the database explaining that comparisons of karyotype abnormalities were not performed between both groups. However, procedure can be adjusted, since risk factors other than age do not change with age. This means that patients with a high-risk for leukemia (eg multiple complex chromosomal abnormalities) and low risk for transplant-related mortality (eg male donor, male recipient) could receive a bone marrow transplant, even at 50 years of age. In contrast, patients with low risk for leukemia (eg M4 Eos + inv 16) but a high risk for transplant-related mortality (eg male recipient female donor) should not have a transplant in first CR. Also, in patients aged more than 40-45, new approaches to decrease TRM are warranted.
